论文部分内容阅读
目的:探讨曲美布汀联合思连康治疗功能性便秘病人的临床疗效及安全性。方法:回顾性分析我院2013年5月至2014年6月期间收治的78例功能性便秘病人的临床资料,采用数字单双号的模式分为对照组(单用曲美布汀)与治疗组(曲美布汀联合思连康),每组各39例。对比两组病人的治疗总有效率与不良反应发生率。结果:通过治疗,治疗组病人的治疗总有效率明显优于对照组,(P<0.05)差异具有统计学意义;两组病人的不良反应对比不具有统计学意义(P>0.05)。结论:针对功能性便秘病人,采用曲美布汀联合思量康进行治疗能够有效提升临床疗效,并且具有良好的安全性,对提升病人的生活质量具有十分重要的现实意义。
Objective: To investigate the clinical efficacy and safety of Trimebutine combined with Si Lian Kang in the treatment of patients with functional constipation. Methods: The clinical data of 78 patients with functional constipation treated in our hospital from May 2013 to June 2014 were retrospectively analyzed. The patients were divided into control group (trimebutine alone) and treatment Group (Trimebutine combined with Silian Kang), 39 cases in each group. The total effective rate and adverse reaction rate of two groups were compared. Results: The total effective rate of treatment group was significantly better than that of control group (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: For patients with functional constipation, the use of trimebutine combined with Sikang Kang treatment can effectively improve the clinical efficacy, and has good safety, to improve the quality of life of patients with very important practical significance.